





BACKGROUND:

- Irritable bowel syndrome (IBS) is a functional disease with persistent gastrointestinal symptoms classified into four subtypes that affects 10–23% of adults globally, according to 2022 global research trends.¹
- Serotonin (5-hydroxytryptamine [5-HT]) plays a crucial role in the contraction and relaxation of smooth muscle. Intraluminal distension stimulates the release of endogenous 5-HT, activating 5-HT3 receptors, leading to increased intestinal secretions and peristaltic activity.²
- Ramosetron, a potent and selective 5-HT3 receptor antagonist, is developed for diarrhoea-predominant IBS management.

SCHEMATIC REPRESENTATION OF IBS PATHOPHYSIOLOGY³:



IBS-ASSOCIATED COMORBIDITIES⁴:




CLINICAL EVIDENCES:

RANDOMIZED, PLACEBO-CONTROLLED, PHASE IV PILOT STUDY OF RAMOSETRON TO EVALUATE THE CO-PRIMARY ENDPOINTS IN MALE PATIENTS WITH IRRITABLE BOWEL SYNDROME WITH DIARRHEA.⁵

Patients: Ramosetron Group (n = 47), Placebo Group (n = 51) Dose: Placebo or Ramosetron HCL 5 mcg OD before breakfast Duration: 12 Weeks

Result:



Improvement in symptoms of the chief complaint that patients had before administration of the study drug

Conclusion:

Ramosetron most effectively improves stool consistency, a clinically meaningful endpoint for individual with IBS symptoms.


A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED CLINICAL TRIAL OF THE EFFECTIVENESS OF RAMOSETRON IN PATIENTS WITH DIARRHEA-PREDOMINANT IRRITABLE BOWEL SYNDROME⁶

Patients: 539 Patients with IBS-D (Ramosetron HCL=270 and Placebo=269)

Dose: 5 mcg of Ramosetron HCL or Placebo OD

Duration: 12 Weeks

Result:



Monthly responder rate of "Patient-reported global assessment of relief of IBS symptoms".

Conclusion:

Ramosetron hydrochloride 5 mcg once daily is effective and well tolerated in the treatment of abdominal pain, discomfort, and bowel habits in patients with diarrhoea-predominant irritable bowel syndrome.



DESCRIPTION:


RAMLAREN contains ramosetron HCL and is available in the strength of 5 mcg as uncoated tablets. Ramosetron, a potent selective 5-hydroxytryptamine 3 receptor antagonist has been developed and approved at a dosage of 5 mcg for IBS-D.

INDICATION:

Indicated in the treatment of adult patients with diarrhoea-predominant irritable bowel syndrome.

MECHANISM OF ACTION:

Ramosetron in IBS-D works by blocking 5-HT3 receptors. By inhibiting 5-HT3 receptors, It helps regulate intestinal secretions and peristaltic activity, alleviating symptoms in patients with diarrhea-predominant irritable bowel syndrome (IBS-D).



DOSAGE:

The recommended dose of Ramlaren is once daily or as directed by a Physician.

PRESENTATION:

RAMLAREN is available as a strip of 15 Tablets.

References:

- 1. Trends in Irritable Bowel Syndrome, 1 June 2022 | Volume 9
- 2. Clinical and Experimental Gastroenterology 2013:6 123-128
- 3. Frontiers in Cellular and Infection Microbiology/September 2020 | Volume 10 4. doi:10.1038/nrdp.2016.14, 24 March 2016
- 5. Ida et al. BioPsychoSocial Medicine (2017) 11:8
- 6. Scandinavian Journal of Gastroenterology, 2008; 43: 1202_1211
- 7. The Journal of Physiological Sciences (2022)
- 8. Efficacy of ramosetron in the treatment of IBS male patients, Volume 23

La Renon Healthcare Private Limited

207-208 Iscon Elegance, Circle P, Prahlad Nagar Cross Roads, S.G. Highway, Ahmedabad-380015, Gujarat, India. Phone : 91-79-66168998 / 26936656 | Fax: +91-66168998 E-mail :info@larenon.com | Web : www.larenon.com



©2024 All rights reserved, La Renon Healthcare Private Limited